Background Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal
type I collagen bone matrix which typically results in multiple fractures with little or no
trauma. Bisphosphonates are used in an attempt to increase bone mineral density and
reduce these fractures in people with osteogenesis imperfecta. This is an update of a
previously published Cochrane Review. Objectives To assess the effectiveness and safety
of bisphosphonates in increasing bone mineral density, reducing fractures and improving …